This trial looks at abemaciclib as a possible treatment for breast cancer in patients age 70 and older.
- Metastatic Breast Cancer
- Hormone Receptor-positive Breast Cancer
- Stage IV Breast Cancer
1 Primary · 15 Secondary · Reporting Duration: Up to 2 years post treatment
Side Effects for
1 Treatment Group
1 of 1
40 Total Participants · 1 Treatment Group
Primary Treatment: Abemaciclib · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 65+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has Abemaciclib received confirmation from the FDA?
"Abemaciclib was ranked a 2 on our safety scale due to the absence of efficacy data, though clinical studies have been conducted to assess its security." - Anonymous Online Contributor
Is this empirical research pioneering in nature?
"Presently, Abemaciclib is the subject of 92 running trials across 1276 municipalities and 41 nations. Since its initial trial in 2009 (conducted by Eli Lilly & Co., with 220 participants for Phase 1 drug approval) 209 studies have been carried out." - Anonymous Online Contributor
What indications are most often linked to Abemaciclib administration?
"Abemaciclib can be employed to address high-risk cases of recurrent, advanced HR+/HER2- breast cancer and endocrine therapy." - Anonymous Online Contributor
Is enrollment still open for this experiment?
"Clinicaltrials.gov confirms that this medical trial is currently enlisting study participants; it was first announced on March 25th 2020 and the most recent update came out November 1st 2022." - Anonymous Online Contributor
How many participants have been recruited for this research project?
"Affirmative. The details found on clinicaltrials.gov verify that this medical investigation is actively recruiting participants, having first been posted in March of 2020 and edited most recently in November 2022. In total, 40 individuals are needed to be recruited from one site." - Anonymous Online Contributor